MedTrace Logo

Childhood Asthma Perception Study

NCT02702687 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 363

Last updated 2023-02-06

No results posted yet for this study

Summary

This randomized controlled trial will include Latino and Black adolescents with asthma ages 10-17 years old and their caregivers. Participants will be recruited from clinics in the Bronx, New York. The primary aims are to examine the efficacy of peak expiratory flow (PEF) prediction with feedback versus control feedback on 1) under-perception of asthma symptoms 2) controller medication adherence and 3) asthma control and emergency health care use. These aims will be examined across a 1-year follow-up. An exploratory aim examines the hypothesized pathway that the PEF intervention reduces under-perception of symptoms, shifts illness representations toward the professional model and increases adolescents' and parents' asthma management self-efficacy, resulting in greater medication adherence and improved asthma control.

Conditions

Interventions

BEHAVIORAL

PEF Feedback

Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.

BEHAVIORAL

Control Feedback

Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Albert Einstein College of Medicine

    lead OTHER

Principal Investigators

  • Jonathan Feldman, PhD · Albert Einstein College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2022-07-28
Completion
2022-07-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702687 on ClinicalTrials.gov